N
Neoplas Med
Based on the INP research into plasma medicine, the emerging company develops innovative products for medical applications
About Neoplas Med
Neoplas Med GmbH is a German medical technology company established in 2009 as a spin-off from the Leibniz Institute for Plasma Science and Technology (INP) in Greifswald. The company leverages foundational research from the INP to create products for medical applications, operating within the growing plasma medicine market. This market, focused on wound care, is projected to expand significantly, driven by an aging population and the rising prevalence of chronic diseases.
The company's business model centers on the development, production, and sale of its cold plasma devices to healthcare providers. Its primary clientele includes university clinics, hospitals, and medical practices. Revenue is generated through the sale of the kINPen® MED device and associated sterile components. Neoplas Med has secured significant investment to scale its operations, with Niterra Ventures Company being a key strategic partner, investing a total of $25 million across several funding rounds to support international expansion and technology development.
The flagship product is the kINPen® MED, a handheld atmospheric pressure plasma jet. This was the first device of its kind to receive CE marking for treating chronic wounds and pathogen-induced skin disorders and is also MDR certified, a standard met by only a small percentage of European MedTech companies. The device works by applying a jet of cold argon plasma, at a temperature below 40°C, to the wound surface without direct contact. This process has a triple-action effect: it inactivates a broad spectrum of pathogens, including multi-resistant bacteria like MRSA; it promotes microcirculation to improve nutrient and oxygen supply; and it stimulates tissue regeneration. Clinical studies have demonstrated that this technology can reduce wound healing time by up to 50% compared to conventional methods, with no known side effects or risk of developing resistance. The precise, pen-like application makes it suitable for complex wounds with cavities and uneven surfaces.
A significant milestone was the approval for a trial study by Germany's Federal Joint Committee (G-BA) in 2021, a crucial step towards reimbursement by statutory health insurance, based on promising clinical data. The technology is currently used in 75% of German university clinics and has been utilized in over 500,000 treatments globally, with a presence in leading clinics across Europe and the Middle East. Ulrike Sailer has served as the CEO and managing partner since the end of 2019.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Nov 2024 | $18M | $72M | Venture Lab Niterra | ↗ |
| SEED✓Equity / VC | Jan 2022 | $7M | $28M | Venture Lab Niterra | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Neoplas Med is 3.6K monthly website visits, up 125% over the last three months. Neoplas Med's team grew 17.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
Clair ScientificAffordable automated microscopes delivering top-tier speed and optical performance |
Herlev, Denmark | Operational | 5 | $2.2M | $7M |
BearmindWearable technology to prevent brain injuries in sports |
Lausanne, Switzerland | Operational | |||
TrianecTPortable pre-hospital stroke diagnosis for ambulance services |
Utrecht, Netherlands | Operational | |||
REVISION IMPLANTBreakthrough neurotechnology for blind people |
Oud-Heverlee, Belgium | Operational | |||
AlivionEmpowering Health Decisions Through Breath Analysis |
Opfikon, Switzerland | Operational | |||
VenoVisionNon-invasive hemodynamic monitoring for heart failure & at-risk patients in the hospital and at home using ML + thermal imaging |
Wilmington, United States | Operational | |||
BionicMRobotic-powered prosthetic knees for lower-limb amputees |
Tokyo, Japan | Operational | |||
The Portray System3D Intraoral X-ray Imaging Systems |
Morrisville, United States | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Neoplas Med in the Greifswald ecosystem
The Neoplas Med office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Venture Lab Niterra
Other known investors2 additional known investors
Leibniz Association
Leibniz Institute for Plasma Science and Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Neoplas Med on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Neoplas Med’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









